Upadacitinib, an oral Janus kinase-1 (JAK-1)-selective inhibitor, is used to treat moderate to severe forms of rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis (Table 8). The gene discussed is JAK1; the disease is rheumatoid arthritis.